An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
The primary objective of this study is to assess the overall survival (OS) of oral linifanib given as monotherapy once daily (QD) compared to sorafenib given twice daily (BID) per standard of care in subjects with advanced or metastatic HCC.
The IDMC recommended discontinuation of the study, and, the protocol was amended to end study treatment.
Inclusion Criteria
Exclusion Criteria
LaVerne, California 91750, United States
Rosario, Santa Fe, S2002KDS, Argentina
Hokkaido, Japan
Ibaraki-ken, Japan
Tochigi-ken, Japan
Petaling Jaya, Selangor, 46050, Malaysia
Durango, DGO., CP 34000, Mexico
Jeollanam-do, 519-809, South Korea
Kaohsiung County, 833, Taiwan